Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats

Behavioural Brain Research

Volumn 279, Issue , 2015, Pages 274-282

  Tan, Liang ^a   Ge, Gongfei ^a   Tang, Jun ^a   Fu, Chuhua ^a   Duanmu, Wangsheng ^a   Chen, Yujie ^a   Hu, Rong ^a   Sui, Jianfeng ^a   Liu, Xin ^a   Feng, Hua ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Amantadine; Depression; Dopamine; Nigrostriatal pathway; Traumatic brain injury

Indexed keywords

AMANTADINE; DOPAMINE; ANTIDEPRESSANT AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG MEGADOSE; LOW DRUG DOSE; MALE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; RAT; SUBSTANTIA NIGRA; TRAUMATIC BRAIN INJURY; ANIMAL; BRAIN INJURY; CHEMISTRY; COMPLICATION; DRUG EFFECTS; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

AMANTADINE; ANIMALS; ANTIDEPRESSIVE AGENTS; APOPTOSIS; BRAIN INJURIES; CORPUS STRIATUM; DEPRESSION; DOPAMINE; DOPAMINERGIC NEURONS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 84916620686     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.10.037     Document Type: Article

References (60)

1. Hu J., Ugiliweneza B., Meyer K., Lad S.P., Boakye M. Trend and geographic analysis for traumatic brain injury mortality and cost based on MarketScan database. J Neurotrauma 2013, 30:1755-1761.
2. Langlois J.A., Rutland-Brown W., Wald M.M. The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil 2006, 21:375-378.
3. Stein D.J., Seedat S., Iversen A., Wessely S. Post-traumatic stress disorder: medicine and politics. Lancet 2007, 369:139-144.
4. Zaloshnja E., Miller T., Langlois J.A., Selassie A.W. Prevalence of long-term disability from traumatic brain injury in the civilian population of the United States, 2005. J Head Trauma Rehabil 2008, 23:394-400.
5. Bryant R.A., O'Donnell M.L., Creamer M., McFarlane A.C., Clark C.R., Silove D. The psychiatric sequelae of traumatic injury. Am J Psychiatry 2010, 167:312-320.
6. O'Donnell M.L., Creamer M., Pattison P., Atkin C. Psychiatric morbidity following injury. Am J Psychiatry 2004, 161:507-514.
7. Ownsworth T.L., Oei T.P. Depression after traumatic brain injury: conceptualization and treatment considerations. Brain Inj 1998, 12:735-751.
8. Williams W.H., Evans J.J. Brain injury and emotion: an overview to a special issue on biopsychosocial approaches in neurorehabilitation. Neuropsychol Rehabil 2003, 13:1-11.
9. Balasubramani P.P., Chakravarthy V.S., Ravindran B., Moustafa A.A. An extended reinforcement learning model of basal ganglia to understand the contributions of serotonin and dopamine in risk-based decision making, reward prediction, and punishment learning. Front Comput Neurosci 2014, 8:47.
10. Wen X., Wu X., Liu J., Li K., Yao L. Abnormal baseline brain activity in non-depressed Parkinson's disease and depressed Parkinson's disease: a resting-state functional magnetic resonance imaging study. PLoS ONE 2013, 8:e63691.
11. Piotrowska A., Siwek A., Wolak M., Pochwat B., Szewczyk B., Opoka W., et al. Involvement of the monoaminergic system in the antidepressant-like activity of chromium chloride in the forced swim test. J Physiol Pharmacol 2013, 64:493-498.
12. Penmatsa A., Wang K.H., Gouaux E. X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 2013, 503:85-90.
13. Hu Z., Cooper M., Crockett D.P., Zhou R. Differentiation of the midbrain dopaminergic pathways during mouse development. J Comp Neurol 2004, 476:301-311.
14. Tye K.M., Mirzabekov J.J., Warden M.R., Ferenczi E.A., Tsai H.C., Finkelstein J., et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 2013, 493:537-541.
15. Park S.K., Nguyen M.D., Fischer A., Luke M.P., Affar el B., Dieffenbach P.B., et al. Par-4 links dopamine signaling and depression. Cell 2005, 122:275-287.
16. Bakay R.A., Sweeney K.M., Wood J.H. Pathophysiology of cerebrospinal fluid in head injury: part 1. Pathological changes in cerebrospinal fluid solute composition after traumatic injury. Neurosurgery 1986, 18:234-243.
17. Zhang Q.J., Wang S., Liu J., Ali U., Gui Z.H., Wu Z.H., et al. Unilateral lesion of the nigrostriatal pathway decreases the response of interneurons in medial prefrontal cortex to 5-HT 2A/2C receptor stimulation in the rat. Brain Res 2010, 1312:127-137.
18. Wang T., Huang X.J., Van K.C., Went G.T., Nguyen J.T., Lyeth B.G. Amantadine improves cognitive outcome and increases neuronal survival after fluid percussion traumatic brain injury in rats. J Neurotrauma 2014, 31:370-377.
19. Peeters M., Page G., Maloteaux J.M., Hermans E. Hypersensitivity of dopamine transmission in the rat striatum after treatment with the NMDA receptor antagonist amantadine. Brain Res 2002, 949:32-41.
20. Giacino J.T., Whyte J., Bagiella E., Kalmar K., Childs N., Khademi A., et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med 2012, 366:819-826.
21. Sawyer E., Mauro L.S., Ohlinger M.J. Amantadine enhancement of arousal and cognition after traumatic brain injury. Ann Pharmacother 2008, 42:247-252.
22. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
23. Rogoz Z., Skuza G., Daniel W.A., Wojcikowski J., Dudek D., Wrobel A. Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep 2007, 59:778-784.
24. Roman A., Rogoz Z., Kubera M., Nawrat D., Nalepa I. Concomitant administration of fluoxetine and amantadine modulates the activity of peritoneal macrophages of rats subjected to a forced swimming test. Pharmacol Rep 2009, 61:1069-1077.
25. Feeney D.M., Boyeson M.G., Linn R.T., Murray H.M., Dail W.G. Responses to cortical injury: I. Methodology and local effects of contusions in the rat. Brain Res 1981, 211:67-77.
26. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 1987, 93:358-364.
27. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245.
28. Ehara A., Ueda S. Application of Fluoro-Jade C in acute and chronic neurodegeneration models: utilities and staining differences. Acta Histochem Cytochem 2009, 42:171-179.
29. Alimoradian A., Sajedianfard J., Baha-Aldini Beigy F., Panjehshahin M.R., Owji A.A. Relationship of dopamine of the nucleus accumbens with intra-infralimbic apomorphine microinjection. Iran J Basic Med Sci 2013, 16:743-750.
30. Thurman D., Guerrero J. Trends in hospitalization associated with traumatic brain injury. JAMA 1999, 282:954-957.
31. Incidence rates of hospitalization related to traumatic brain injury--12 states, 2002. MMWR 2006, 55:201-204.
32. Gordon W.A., Brown M., Sliwinski M., Hibbard M.R., Patti N., Weiss M.J., et al. The enigma of "hidden" traumatic brain injury. J Head Trauma Rehabil 1998, 13:39-56.
33. Hibbard M.R., Uysal S., Sliwinski M., Gordon W.A. Undiagnosed health issues in individuals with traumatic brain injury living in the community. J Head Trauma Rehabil 1998, 13:47-57.
34. Hoge C.W., McGurk D., Thomas J.L., Cox A.L., Engel C.C., Castro C.A. Mild traumatic brain injury in U.S. Soldiers returning from Iraq. N Engl J Med 2008, 358:453-463.
35. Hibbard M.R., Bogdany J., Uysal S., Kepler K., Silver J.M., Gordon W.A., et al. Axis II psychopathology in individuals with traumatic brain injury. Brain Inj 2000, 14:45-61.
36. Rao V., Bertrand M., Rosenberg P., Makley M., Schretlen D.J., Brandt J., et al. Predictors of new-onset depression after mild traumatic brain injury. J Neuropsychiat Clin Neurosci 2010, 22:100-104.
37. Barker-Collo S., Starkey N., Theadom A. Treatment for depression following mild traumatic brain injury in adults: a meta-analysis. Brain Inj 2013, 27:1124-1133.
38. Braestrup C., Andersen H., Randrup A. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur J Pharmacol 1975, 34:181-187.
39. Leggio G.M., Salomone S., Bucolo C., Platania C., Micale V., Caraci F., et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol 2013, 719:25-33.
40. Lambert G., Johansson M., Agren H., Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry 2000, 57:787-793.
41. van Bregt D.R., Thomas T.C., Hinzman J.M., Cao T., Liu M., Bing G., et al. Substantia nigra vulnerability after a single moderate diffuse brain injury in the rat. Exp Neurol 2012, 234:8-19.
42. Wong J.C., Hazrati L.N. Parkinson's disease, parkinsonism, and traumatic brain injury. Crit Rev Clin Lab Sci 2013, 50:103-106.
43. Shin S.S., Bales J.W., Yan H.Q., Kline A.E., Wagner A.K., Lyons-Weiler J., et al. The effect of environmental enrichment on substantia nigra gene expression after traumatic brain injury in rats. J Neurotrauma 2013, 30:259-270.
44. Eakin K., Hoffer B., Miller J. Substantia nigra vulnerability after a single moderate diffuse brain injury in the rat. Exp Neurol 2013, 240:103-107.
45. Hutson C.B., Lazo C.R., Mortazavi F., Giza C.C., Hovda D., Chesselet M.F. Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J Neurotrauma 2011, 28:1783-1801.
46. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007, 64:327-337.
47. Kulkarni S.K., Dhir A. Current investigational drugs for major depression. Expert Opin Invest Drugs 2009, 18:767-788.
48. Nayernouri T. Posttraumatic parkinsonism. Surg Neurol 1985, 24:263-264.
49. Patel J., Mooslehner K.A., Chan P.M., Emson P.C., Stamford J.A. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. J Neurochem 2003, 85:898-910.
50. Shimada R., Abe K., Furutani R., Kibayashi K. Changes in dopamine transporter expression in the midbrain following traumatic brain injury: an immunohistochemical and in situ hybridization study in a mouse model. Neurol Res 2014, 36:239-246.
51. Massucci J.L., Kline A.E., Ma X., Zafonte R.D., Dixon C.E. Time dependent alterations in dopamine tissue levels and metabolism after experimental traumatic brain injury in rats. Neurosci Lett 2004, 372:127-131.
52. Huang E.Y., Tsai T.H., Kuo T.T., Tsai J.J., Tsui P.F., Chou Y.C., et al. Remote effects on the striatal dopamine system after fluid percussion injury. Behav Brain Res 2014, 267:156-172.
53. Harsing L. Dopamine and the dopaminergic systems of the brain. The handbook of neurochemistry and molecular neurobiology: neural membranes and transport 2008, 149-170. Springer, Berlin. 3rd ed. A. Lajtha (Ed.).
54. Huang E.Y., Tsui P.F., Kuo T.T., Tsai J.J., Chou Y.C., Ma H.I., et al. Amantadine ameliorates dopamine-releasing deficits and behavioral deficits in rats after fluid percussion injury. PLOS ONE 2014, 9:e86354.
55. Fritschy J.M., Grzanna R. Restoration of ascending noradrenergic projections by residual locus coeruleus neurons: compensatory response to neurotoxin-induced cell death in the adult rat brain. J Comp Neurol 1992, 321:421-441.
56. Yan H.Q., Kline A.E., Ma X., Li Y., Dixon C.E. Traumatic brain injury reduces dopamine transporter protein expression in the rat frontal cortex. Neuroreport 2002, 13:1899-1901.
57. Lee H., Kim S.W., Kim J.M., Shin I.S., Yang S.J., Yoon J.S. Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury. Hum Psychopharmacol 2005, 20:97-104.
58. Pristupa Z.B., McConkey F., Liu F., Man H.Y., Lee F.J., Wang Y.T., et al. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse (New York, NY) 1998, 30:79-87.
59. Parsons C.G., Panchenko V.A., Pinchenko V.O., Tsyndrenko A.Y., Krishtal O.A. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 1996, 8:446-454.
60. Ossola B., Schendzielorz N., Chen S.H., Bird G.S., Tuominen R.K., Mannisto P.T., et al. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia. Neuropharmacology 2011, 61:574-582. [corrected].